NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $18.22 -0.42 (-2.25%) Closing price 09/30/2026 04:00 PM EasternExtended Trading$18.34 +0.12 (+0.63%) As of 06:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sarepta Therapeutics Stock (NASDAQ:SRPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sarepta Therapeutics alerts:Sign Up Key Stats Today's Range$18.06▼$18.6950-Day Range$14.86▼$23.2152-Week Range$14.68▼$25.32Volume1.99 million shsAverage Volume2.86 million shsMarket Capitalization$1.92 billionP/E RatioN/ADividend YieldN/APrice Target$23.81Consensus RatingHold Company Overview Sarepta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. Its research platforms include RNA-based technologies, gene therapy and gene-editing approaches designed to address the underlying causes of genetic disorders. The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for eligible patients with specific genetic mutations, as well as Elevidys, a gene therapy developed to treat certain patients with DMD. Sarepta also maintains a pipeline of investigational medicines for rare neuromuscular and central nervous system conditions. Originally known as AVI BioPharma, the company changed its name to Sarepta Therapeutics in 2012. Headquartered in Cambridge, Massachusetts, Sarepta serves patients primarily through the U.S. market and pursues regulatory approvals and commercial opportunities internationally. Douglas S. Ingram has served as the company’s president and chief executive officer since 2017.AI Generated. May Contain Errors. Read More Sarepta Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreSRPT MarketRank™: Sarepta Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 369th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingSarepta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on no strong buy ratings, 8 buy ratings, 7 hold ratings, and 6 sell ratings.Upside PotentialSarepta Therapeutics has a consensus price target of $23.81, representing about 30.7% upside from its current price of $18.22.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-48.44% Earnings GrowthEarnings for Sarepta Therapeutics are expected to decrease by -48.44% in the coming year, from $3.53 to $1.82 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioSarepta Therapeutics has a PEG Ratio of 0.27. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.86% of the float of Sarepta Therapeutics has been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 8.02.Change versus previous monthShort interest in Sarepta Therapeutics has recently increased by 3.30%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.46 News SentimentSarepta Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Sarepta Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 9 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows6 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRPT Stock News HeadlinesSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 30 at 6:16 PM | finance.yahoo.comSarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with DuchenneSeptember 30 at 1:15 PM | finance.yahoo.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 1 at 1:00 AM | Investors Alley (Ad)Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with DuchenneSeptember 30 at 9:00 AM | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT), BioNTech SE (BNTX) and AgomAb Therapeutics NV ADR (AGMB)September 29 at 5:08 PM | theglobeandmail.comNeedham & Company LLC Reaffirms Underperform Rating for Sarepta Therapeutics (NASDAQ:SRPT)September 28 at 8:07 AM | americanbankingnews.comWhy Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPennSeptember 26, 2026 | finance.yahoo.comSarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual CongressSeptember 25, 2026 | finance.yahoo.comSee More Headlines SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $21.52 on January 1st, 2026. Since then, SRPT shares have decreased by 15.3% and is now trading at $18.22. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.42. The business's revenue for the quarter was down 34.3% on a year-over-year basis. Read the conference call transcript. Does Sarepta Therapeutics have any subsidiaries? Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN). Company Calendar Last Earnings8/05/2026Today10/01/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SRPT's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CIK873303 Webwww.sarepta.com Phone(617) 274-4000Fax425-354-5038Employees835Year Founded1980Price Target and Rating Average Price Target for Sarepta Therapeutics$23.81 High Price Target$38.00 Low Price Target$13.00 Potential Upside/Downside+30.7%Consensus RatingHold Rating Score (0-4)2.10 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($2.90) Trailing P/E RatioN/A Forward P/E Ratio5.16 P/E Growth0.27Net Income-$713.41 million Net Margins-13.48% Pretax Margin-6.63% Return on Equity-1.60% Return on Assets-0.66% Debt Debt-to-Equity Ratio0.55 Current Ratio4.42 Quick Ratio2.62 Sales & Book Value Annual Sales$1.97 billion Price / Sales0.97 Cash FlowN/A Price / Cash FlowN/A Book Value$10.89 per share Price / Book1.67Miscellaneous Outstanding Shares105,627,000Free Float98,339,000Market Cap$1.92 billion OptionableOptionable Beta0.27 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SRPT) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
